Moxonidine

DRUG12 trials

Conditions

Abdominal ObesityArterial HypertensionAtrial FibrillationCardiac DiseaseDiabetic NephropathiesHypertensionMetabolic SyndromeObesity

Early Phase 1

Autonomic Determinants of POTS - Pilot1

Active, not recruitingNCT04050410

Vanderbilt University Medical CenterPostural Tachycardia Syndrome

Start: 2019-08-27End: 2026-12-31Target: 48Updated: 2026-03-27

Phase 1

Sympathetic Mechanisms in Obesity-Crossover Design

RecruitingNCT05312892

Vanderbilt University Medical CenterHypertension, Obesity

Start: 2022-05-20End: 2030-12-31Target: 12Updated: 2026-02-27

Phase 3

Efficacy and Safety of Moxonidine in Indian Patients

CompletedNCT00160277

Solvay PharmaceuticalsHypertension

Start: 2005-07-31Target: 100Updated: 2009-01-30

Moxonidine in Patients Undergoing Vascular Surgery

TerminatedNCT00244504

University Hospital, Basel, SwitzerlandCardiac Disease, Vascular Surgery

Start: 2002-11-30End: 2006-03-31Updated: 2009-11-10

Phase 4

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

CompletedNCT01094769

Baker Heart and Diabetes InstituteDiabetic Nephropathies

Start: 2011-04-30End: 2020-04-30Target: 48Updated: 2023-09-14

Treatment of Adiposity Related hypErTension (TARGET)

CompletedNCT01138423

UMC UtrechtAbdominal Obesity, Hypertension, Metabolic Syndrome

Start: 2010-08-31End: 2012-02-29Updated: 2012-02-24

The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension

NCT01360710

Baker Heart and Diabetes InstituteAbdominal Obesity, Hypertension

Start: 2012-01-31Target: 100Updated: 2012-02-03

Polycystic Ovary Syndrome - Improving Outcomes

CompletedNCT01504321

Baker Heart and Diabetes InstitutePolycystic Ovary Syndrome

Start: 2012-05-31End: 2015-12-31Updated: 2018-11-02

Alleviating the Metabolic Side Effects of Antipsychotic Medications

WithdrawnNCT01567124

Baker Heart and Diabetes InstituteSchizophrenia

Start: 2012-05-31Updated: 2019-04-24

Moxonidine for Prevention of Post-ablation AFib Recurrences

CompletedNCT01791699

Spyridon DeftereosAtrial Fibrillation

Start: 2012-08-31End: 2014-04-30Target: 150Updated: 2014-05-06

Moxonidine Effects on Neuropeptide Y

CompletedNCT05147753

Aristotle University Of ThessalonikiHypertension, Obesity

Start: 2010-01-11End: 2014-06-30Updated: 2021-12-07

Unknown Phase

Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women

CompletedNCT02355821

National Research Center for Preventive MedicineArterial Hypertension, Osteopenia

Start: 2015-04-30End: 2018-07-10Updated: 2021-09-01

2020-08-262 citations

Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome-A Randomized Controlled Trial.

2018-10-2510 citations

Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation

Journal of Cardiovascular Pharmacology2018-10-243 citations

Identifying treatment response to antihypertensives in patients with obesity-related hypertension

Clinical Hypertension2017-09-276 citations

Central Sympathetic Inhibition to Reduce Postablation Atrial Fibrillation Recurrences in Hypertensive Patients

Circulation2014-08-2231 citations

Randomized clinical trial of moxonidine in patients undergoing major vascular surgery.

2007-12-017 citations